Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Schizophrenia and Bipolar Disorder: A Systematic Review.

Autor: Liberona A; Escuela de Medicina, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile., Jones N; Escuela de Medicina, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile., Zúñiga K; Escuela de Medicina, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile., Garrido V; Escuela de Medicina, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile., Zelada MI; Escuela de Medicina, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile., Silva H; Clínica Psiquiátrica Universitaria, Hospital Clínico de la Universidad de Chile, Universidad de Chile, Santiago 8380453, Chile.; Departamento de Psiquiatría y Salud Mental Norte, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile., Nieto RR; Clínica Psiquiátrica Universitaria, Hospital Clínico de la Universidad de Chile, Universidad de Chile, Santiago 8380453, Chile.; Departamento de Psiquiatría y Salud Mental Norte, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.; Departamento de Neurociencias, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2024 Oct 18; Vol. 25 (20). Date of Electronic Publication: 2024 Oct 18.
DOI: 10.3390/ijms252011204
Abstrakt: Brain-derived neurotrophic factor (BDNF) is a potential biomarker of response to treatment in psychiatric disorders. As it plays a role in the pathophysiological development of schizophrenia and bipolar disorder, it is of interest to study its role in predicting therapeutic responses in both conditions. We carried out a systematic review of the literature, looking for differences in baseline BDNF levels and the Val66Met BDNF polymorphism in these disorders between responders and non-responders, and found information showing that the Val/Val genotype and higher baseline BDNF levels may be present in patients that respond successfully to pharmacological and non-pharmacological treatments. However, there is still limited evidence to support the role of the Val66Met polymorphism and baseline BDNF levels as predictors of treatment response.
Databáze: MEDLINE
Externí odkaz: